News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Sanofi (France)'s Sleep Driving Drug Should Remain on the Shelves Says Australian Therapeutic Goods Administration
July 10, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
An insomnia treatment linked to sleepwalking and sleep driving should stay on the market according to the Australian Therapeutic Good Administration (TGA).
Twitter
LinkedIn
Facebook
Email
Print
Asia
Australia
Sanofi (France)
MORE ON THIS TOPIC
Insights
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
January 7, 2026
·
3 min read
·
Jennifer Smith-Parker
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
China
BMS Forges $1B+ Antibody Alliance With Chinese Firm Harbour
December 17, 2025
·
1 min read
·
Tristan Manalac
Podcast
Lilly’s Triple Triumph, Prasad’s COVID Error, J&J’s Surprise Voucher, M&A Targets
December 17, 2025
·
2 min read
·
Heather McKenzie
